<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19552" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cicatricial Pemphigoid</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tolaymat</surname>
            <given-names>Leila</given-names>
          </name>
          <aff>Mayo Clinic Jacksonville</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hall</surname>
            <given-names>Matthew R.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Leila Tolaymat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Hall declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19552.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cicatricial pemphigoid is a rare, chronic autoimmune blistering disorder which can produce scarring. It can affect the skin, the mucous membranes, or both. When only mucous membranes are involved, the disease is often referred to as mucous membrane pemphigoid. When only the ocular membranes are involved, it may be referred to as ocular pemphigoid. Risk of scarring depends on the location of disease activity. Initial diagnosis can be a challenge. This activity describes the presentation, evaluation, and management of cicatricial pemphigoid and highlights the role of the interprofessional team in the care of affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of cicatricial pemphigoid.</p></list-item><list-item><p>Summarize the presentation of cicatricial pemphigoid.</p></list-item><list-item><p>Outline the treatment and management options available for cicatricial pemphigoid.</p></list-item><list-item><p>Explain a well-coordinated interprofessional team approach to provide effective care to patients affected by cicatricial pemphigoid.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19552&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19552">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19552.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cicatricial pemphigoid is a rare, chronic autoimmune blistering disorder which can produce scarring.&#x000a0;It can affect the skin only, mucous membranes only, or both the skin and mucous membranes. When only mucous membranes are involved, the disease is often referred to as mucous membrane pemphigoid. When only the ocular membranes are involved, it may be&#x000a0;referred to as ocular pemphigoid. Risk of scarring depends on the location of disease activity. Initial diagnosis can be a challenge. Due to the risks of serious complications, such as blindness and airway compromise, early and aggressive treatment initiation may be warranted.</p>
      </sec>
      <sec id="article-19552.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Autoantibodies targeted to components of the basement membrane zone have been identified as pathogenic in cicatricial pemphigoid. Patients with cicatricial pemphigoid may have antibodies detected&#x000a0;to 180-kD bullous pemphigoid antigen (BP180),<xref ref-type="bibr" rid="article-19552.r1">[1]</xref>&#x000a0;laminin 332&#x000a0;(previously known as epiligrin or laminin-5),<xref ref-type="bibr" rid="article-19552.r2">[2]</xref>&#x000a0;beta-4-integrin,<xref ref-type="bibr" rid="article-19552.r3">[3]</xref> and other antigens that are not fully described.</p>
      </sec>
      <sec id="article-19552.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Cicatricial pemphigoid is a rare disorder. The exact prevalence and incidence are not known. The incidence of cicatricial pemphigoid estimated in a French study&#x000a0;was 1.16 per million per year.<xref ref-type="bibr" rid="article-19552.r4">[4]</xref>&#x000a0;The incidence of cicatricial pemphigoid estimated in German study was 0.87 per million per year.<xref ref-type="bibr" rid="article-19552.r5">[5]</xref>&#x000a0;</p>
        <p>In a study out of Greece, the mean age of onset for cicatricial pemphigoid was found to be 66 years of age, and there&#x000a0;was a 1.5:1 female predominance.<xref ref-type="bibr" rid="article-19552.r6">[6]</xref>&#x000a0;Female to male ratio for cicatricial pemphigoid&#x000a0;was reported as high as 7:1&#x000a0;in a German population.<xref ref-type="bibr" rid="article-19552.r5">[5]</xref></p>
        <p>In a recent retrospective chart review of 162 patients with mucous membrane pemphigoid, 67% percent of patients had ocular involvement at presentation. In those without ocular involvement initially, it was estimated that the risk of developing ocular mucous membrane pemphigoid was 0.014 per person-year.<xref ref-type="bibr" rid="article-19552.r7">[7]</xref></p>
        <p>HLA-DQB1*0301 is a disease susceptibility marker for cicatricial pemphigoid.<xref ref-type="bibr" rid="article-19552.r8">[8]</xref></p>
      </sec>
      <sec id="article-19552.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Cicatricial pemphigoid is an antibody-mediated blistering disorder.&#x000a0;The antibodies target&#x000a0;molecules responsible for adhesion&#x000a0;within the basement membrane zone&#x000a0;of the mucosa and/or skin. This disrupts the normal&#x000a0;structure and function&#x000a0;of the basement membrane, which allows for&#x000a0;the epidermis to separate from the dermis. Clinically, this manifests as&#x000a0;blisters and erosions. Several target molecules are associated with the pathogenesis of cicatricial pemphigoid.&#x000a0;</p>
        <p>Laminin 332&#x000a0;is a transmembrane protein that connects alpha-6-beta-4 integrin of the hemidesmosome of the keratinocyte&#x000a0;to the&#x000a0;non-collagenous 1 (NC1)&#x000a0;domain of collagen VII. Collagen VII is the attachment for the anchoring fibrils that secure the basement membrane&#x000a0;to the dermis. Laminin 332 assists in strengthening the attachment of the epidermis to the dermis&#x000a0;from shearing forces.</p>
        <p>BP180 is a transmembrane collagen, also referred to as collagen XVII. It&#x000a0;is a component of the&#x000a0;hemidesmosome of the epithelial cell. The dense plaque of the hemidesmosome binds keratin 5 and keratin 14&#x000a0;within the keratinocyte. BP180 spans the lamina lucida. The non-collagenous portion of the domain&#x000a0;(N-terminus)&#x000a0;is located near the cellular membrane and the collagenous portion of the domain&#x000a0;(C-terminus) spans the lamina lucida and projects into the lamina densa.&#x000a0;Sera from patients with bullous pemphigoid&#x000a0;mainly target the N-terminus of BP180 whereas sera from cicatricial pemphigoid patients target the C-terminus. The variability in the target may explain the clinical differences seen among bullous pemphigoid and cicatricial pemphigoid patients.<xref ref-type="bibr" rid="article-19552.r9">[9]</xref><xref ref-type="bibr" rid="article-19552.r10">[10]</xref>&#x000a0;The target of the N-terminus would&#x000a0;result in&#x000a0;a more superficial blister, unlikely to scar, as seen in bullous pemphigoid. The target of the C-terminus would a result in a deeper separation, which would be more likely to scar, as&#x000a0;seen in cicatricial pemphigoid.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref>&#x000a0;</p>
        <p>Alpha-6-beta-4 integrin&#x000a0;is a&#x000a0;component of the hemidesmosome that binds the transmembrane laminin 332 which attaches to collagen VII. Sera and IgG&#x000a0;fractions&#x000a0;from patients with cicatricial pemphigoid have been shown to target the intracellular portion of alpha-6-beta-4 integrin suggesting that this may have a pathogenic role in cicatricial pemphigoid.<xref ref-type="bibr" rid="article-19552.r12">[12]</xref> A recent study demonstrated that sera from patients with ocular mucous membrane pemphigoid reacted to beta-4 integrin.<xref ref-type="bibr" rid="article-19552.r13">[13]</xref></p>
      </sec>
      <sec id="article-19552.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathologic appearance of cicatricial pemphigoid is a subepidermal blister with dermal lymphohistiocytic infiltrate with variable numbers of neutrophils and eosinophils. This is nonspecific and can be seen in other immunobullous disorders including bullous pemphigoid, linear IgA bullous dermatosis, and epidermolysis bullosa acquisita.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref> Plasma cell infiltrate is more common in mucosal biopsies.<xref ref-type="bibr" rid="article-19552.r14">[14]</xref> Fibrosis may be present in older lesions.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref></p>
      </sec>
      <sec id="article-19552.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The mouth is the most common location for involvement with cicatricial pemphigoid. It may be the only site affected.&#x000a0;All areas of the oral cavity may be involved including the buccal mucosa, gingiva,&#x000a0;tongue, vermillion lips, and palate.<xref ref-type="bibr" rid="article-19552.r6">[6]</xref> The disease may extend to posterior pharynx. Clinical appearance includes desquamative gingivitis, blisters, erosions, and ulcers. Patients with desquamative gingivitis may experience pain or bleeding when brushing teeth.&#x000a0;Long-term inflammation and difficulty in maintaining oral hygiene may lead to caries and&#x000a0;loss of teeth and alveolar bone.<xref ref-type="bibr" rid="article-19552.r15">[15]</xref>&#x000a0;Scarring is uncommon but may present as white reticulated patches or adhesions.<xref ref-type="bibr" rid="article-19552.r15">[15]</xref></p>
        <p>Cicatricial pemphigoid of the ocular mucosa is often progressive. Scar formation can result in blindness. Inflammation may be slowly progressive. The patient may experience non-specific symptoms of&#x000a0;eye irritation, such as burning or excessive tearing.<xref ref-type="bibr" rid="article-19552.r14">[14]</xref> The disease may present in one eye only; however,&#x000a0;over the course of a&#x000a0;couple of years,&#x000a0;the disease typically affects both eyes.<xref ref-type="bibr" rid="article-19552.r16">[16]</xref> Rarely, patients present with frank blisters. Early scarring is first noted in the inferior fornices. Symblepharons&#x000a0;are fibrous strands connecting the conjunctiva&#x000a0;of the lid&#x000a0;to the globe. These are best visualized&#x000a0;when pulling down on the lower eyelid and having the patient look up.<xref ref-type="bibr" rid="article-19552.r16">[16]</xref>&#x000a0;The endstage of this process results in scarring of the entire conjunctival sack, known as ankyloblepharon.<xref ref-type="bibr" rid="article-19552.r16">[16]</xref> This results in the inability for the lid to close completely.<xref ref-type="bibr" rid="article-19552.r16">[16]</xref> The chronic inflammation of the conjunctiva also leads to fibrosis of the lacrimal glands and goblet cells, resulting in decreased tear and mucin production.&#x000a0;Scarring of the lid results in entropion (inward turning of the lid) and trichiasis (in-turning of the eyelashes).<xref ref-type="bibr" rid="article-19552.r16">[16]</xref>&#x000a0;The combination of abrasion of the cornea by entropion and trichiasis, decreased tear production and mucin production, and&#x000a0;loss of lid closure function results in keratinization of the corneal epithelium.<xref ref-type="bibr" rid="article-19552.r16">[16]</xref>&#x000a0;This ultimately results in decreased visual acuity.<xref ref-type="bibr" rid="article-19552.r16">[16]</xref></p>
        <p>Nasopharyngeal involvement is less common. It may present as crusted nasal lesions, epistasis, or chronic sinusitis.<xref ref-type="bibr" rid="article-19552.r17">[17]</xref> Adhesions and scarring can occur between structures, leading to airway obstruction.<xref ref-type="bibr" rid="article-19552.r17">[17]</xref>. This has been reported to result in sleep apnea.<xref ref-type="bibr" rid="article-19552.r17">[17]</xref>. Laryngeal involvement may present as a&#x000a0;sore throat or hoarseness.<xref ref-type="bibr" rid="article-19552.r17">[17]</xref>&#x000a0;If scarring occurs, then the loss of phonation becomes permanent.<xref ref-type="bibr" rid="article-19552.r17">[17]</xref> Tracheostomy has been reported as a necessary life-saving intervention in patients with the severe disease resulting in airway compromise.<xref ref-type="bibr" rid="article-19552.r18">[18]</xref></p>
        <p>Esophageal involvement may present as pain, dysphagia, odynophagia, and stenosis.<xref ref-type="bibr" rid="article-19552.r17">[17]</xref></p>
        <p>Cicatricial pemphigoid of the genital and anal mucosa is rare. Erosions and ulcerations can lead to considerable discomfort of the genital skin. Scarring can lead to narrowing of the urethra and vaginal opening. Stenosis of these structures may require surgical intervention to restore function.<xref ref-type="bibr" rid="article-19552.r19">[19]</xref> The most common symptoms of anal involvement&#x000a0;are pain and spasm.<xref ref-type="bibr" rid="article-19552.r19">[19]</xref></p>
        <p>Cutaneous lesions of cicatricial pemphigoid occur in two clinical presentations. The&#x000a0;first&#x000a0;subtype presents as a&#x000a0;more generalized eruption of tense bullae without scarring. The second&#x000a0;subtype presents as blisters on an erythematous base&#x000a0;occurring in localized areas, resulting in atrophic scarring. This most commonly affects the head and neck area.&#x000a0;Activity in the scalp often leads to alopecia.<xref ref-type="bibr" rid="article-19552.r20">[20]</xref>&#x000a0;Brunsting-Perry pemphigoid, which&#x000a0;was once thought to be a form of cicatricial pemphigoid, presents&#x000a0;as a&#x000a0;scarring bullous eruption of the head and neck skin without mucous membrane involvement. This is now believed to be a phenotype of epidermolysis bullosa acquisita.</p>
      </sec>
      <sec id="article-19552.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Biopsy of lesional skin for histopathology is recommended. (See Histopathology for findings.)</p>
        <p>Biopsy of perilesional skin for direct immunofluorescence (DIF)&#x000a0;is recommended. DIF&#x000a0;typically demonstrates IgG and C3 as a linear band at the basement membrane zone.<xref ref-type="bibr" rid="article-19552.r21">[21]</xref> Linear deposition of IgA at the basement membrane zone is occasionally seen.<xref ref-type="bibr" rid="article-19552.r22">[22]</xref>&#x000a0;To increase sensitivity, multiple and repeated sampling may be warranted.<xref ref-type="bibr" rid="article-19552.r23">[23]</xref></p>
        <p>Indirect immunofluorescence&#x000a0;is recommended;&#x000a0;however, it is only positive in a small percentage of patients. The titer is usually low.<xref ref-type="bibr" rid="article-19552.r21">[21]</xref> IIF on the salt-split skin may show an epidermal or dermal pattern. Indirect immunofluorescence (IIF) shows the presence of IgG or IgA autoantibodies. To increase the diagnostic utility of the IIF,&#x000a0;it has been recommended to perform with a concentrated assay, using salt-split skin study, and evaluate for both the presence of IgG and IgA.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref></p>
        <p>Enzyme-linked immunosorbent assay (ELISA)&#x000a0;testing for the presence of anti-BP180 C terminal domain and anti-laminin 332 may be helpful in diagnosis; however, this may not be readily available through all laboratories.<xref ref-type="bibr" rid="article-19552.r24">[24]</xref><xref ref-type="bibr" rid="article-19552.r25">[25]</xref></p>
      </sec>
      <sec id="article-19552.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>For the mild disease of the oral mucosa and skin, topical therapies can be effective. Moderate to high potency topical steroids, in gel or ointment form,&#x000a0;can be used initially 2 to 3 times per day. The frequency of topical steroid application can be slowly tapered based on patient response. To improve the effectiveness of topical therapies, blotting the area&#x000a0;with a disposable tissue to remove moisture&#x000a0;before&#x000a0;the application of medication may be helpful. Patients may apply the&#x000a0;medication&#x000a0;with a finger or cotton-swab and rub into the affected areas gently for 30 seconds.&#x000a0;Patients should be advised to abstain&#x000a0;from eating or drinking for 30&#x000a0;minutes after application to&#x000a0;increase absorption.<xref ref-type="bibr" rid="article-19552.r26">[26]</xref>&#x000a0;Customized prosthetic devices, such as dental trays, can occlude the topical steroid over the affected sites in the mouth.<xref ref-type="bibr" rid="article-19552.r27">[27]</xref> Calcineurin inhibitors, such as tacrolimus, have also been reported&#x000a0;as a topical therapeutic option.<xref ref-type="bibr" rid="article-19552.r28">[28]</xref>&#x000a0;Complications of long-term use of topical steroids&#x000a0;are uncommon. A cutaneous application may lead to hypopigmentation and atrophy. Although these adverse effects are not commonly seen in the mucous membranes, the risk for oral candidiasis and herpes simplex reactivation is a concern.<xref ref-type="bibr" rid="article-19552.r26">[26]</xref>&#x000a0;In addition to topical therapies, the importance of oral care has been emphasized as a critical part in the treatment of mucous membrane pemphigoid. This consists of brushing teeth with a soft bristle toothbrush twice daily, flossing daily, and visiting the dentist every 3-6 months.<xref ref-type="bibr" rid="article-19552.r26">[26]</xref>&#x000a0;If topical therapies are not effective for mild to moderate disease, then dapsone may be effective.<xref ref-type="bibr" rid="article-19552.r29">[29]</xref> Typical dose ranges from 50 to 200 mg daily. Systemic corticosteroids can be used in addition to the dapsone.</p>
        <p>For mild to moderate ocular involvement, systemic corticosteroids (prednisone 1 to 2 mg/kg/day)&#x000a0;alone or in combination with dapsone can be considered. Proper ocular care is important. Since dry eyes are common with ocular pemphigoid, frequent use of lubricants is recommended in the form of artificial tear drops or&#x000a0;petrolatum-based ointments. Cleansing away excess exudates from the eyes helps to prevent secondary bacterial infections.<xref ref-type="bibr" rid="article-19552.r26">[26]</xref></p>
        <p>For severe or rapidly progressive disease involving the ocular, nasopharyngeal, or anogenital mucosa, a combination of systemic corticosteroids (prednisone 1 to 2 mg/kg/day) plus an additional immunosuppressive agent has been recommended. Immunosuppressive agents that have shown efficacy include azathioprine (1 to 2 mg/kg/day), mycophenolate mofetil (2 to 2.5 g/day) or&#x000a0;cyclophosphamide (1 to 2 mg/kg/day).<xref ref-type="bibr" rid="article-19552.r26">[26]</xref><xref ref-type="bibr" rid="article-19552.r30">[30]</xref><xref ref-type="bibr" rid="article-19552.r31">[31]</xref><xref ref-type="bibr" rid="article-19552.r32">[32]</xref><xref ref-type="bibr" rid="article-19552.r33">[33]</xref>&#x000a0;The goal of adjuvant immunosuppressive therapy is to allow taper of prednisone over 6 to 12 months. Intravenous immunoglobulin has been used with success to treat cicatricial pemphigoid.<xref ref-type="bibr" rid="article-19552.r34">[34]</xref><xref ref-type="bibr" rid="article-19552.r35">[35]</xref> Tumor necrosis factor-alpha inhibitors have been used in the treatment of cicatricial pemphigoid.<xref ref-type="bibr" rid="article-19552.r36">[36]</xref><xref ref-type="bibr" rid="article-19552.r37">[37]</xref> Rituximab has been used alone or as adjuvant therapy for the treatment of mucous membrane pemphigoid.<xref ref-type="bibr" rid="article-19552.r38">[38]</xref><xref ref-type="bibr" rid="article-19552.r39">[39]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-19552.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Bullous pemphigoid is a common&#x000a0;autoimmune subepidermal blistering disorder. Age of onset is 65 to 75 years of age. This typically affects the skin and presents as tense bullae on a normal or urticarial background. This less commonly affects the oral mucosa. Lesions do not cause scarring.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref>&#x000a0;The disease is typically steroid responsive.</p>
        <p>Epidermolysis bullosa acquisita (EBA)&#x000a0;is a rare&#x000a0;autoimmune subepidermal&#x000a0;blistering disorder. The most common clinical&#x000a0;presentation is non-inflammatory tense bullae that&#x000a0;form on extensor surfaces usually triggered by friction or trauma. Common locations for involvement include the hands, elbows, knees, and buttocks. Blisters heal with scars and milia formation. Oral involvement can occur.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref> This can be associated with underlying systemic diseases.<xref ref-type="bibr" rid="article-19552.r40">[40]</xref>&#x000a0;EBA is&#x000a0;recalcitrant to therapy.</p>
        <p>Linear IgA bullous dermatosis is&#x000a0;rare subepidermal bullous dermatosis. Its clinical presentation varies and can mimic bullous pemphigoid, dermatitis herpetiformis, and cicatricial pemphigoid. It may have oral and, less likely, ocular involvement.<xref ref-type="bibr" rid="article-19552.r41">[41]</xref><xref ref-type="bibr" rid="article-19552.r42">[42]</xref></p>
        <p>Bullous systemic lupus erythematosus is an autoimmune subepidermal blistering disorder&#x000a0;that develops&#x000a0;in patients with systemic lupus.&#x000a0;The eruption&#x000a0;consists&#x000a0;of erythematous macules, plaques, and bullae that&#x000a0;tend to occur in sun-exposed areas and do not typically result in scarring. Oral lesions can occur.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref></p>
        <p>Paraneoplastic pemphigus is a rare&#x000a0;autoimmune disease associated with malignancy, most commonly non-Hodgkin lymphoma and chronic lymphocytic leukemia. This is characterized by painful and erosive&#x000a0;stomatitis and polymorphous cutaneous lesions that may resemble bullous pemphigoid, lichen planus or erythema multiforme. Indirect immunofluorescence on rodent bladder can detect serum autoantibodies directed against plakin proteins. This is rapidly progressive and often results in death.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref></p>
        <p>Pseudo-ocular cicatricial pemphigoid is mimicker of cicatricial pemphigoid.&#x000a0;This is a rare complication from the&#x000a0;use of medicated eye drops in the treatment of glaucoma. Eye involvement is unilateral.&#x000a0;Progression usually ceases&#x000a0;once eye drops are discontinued.<xref ref-type="bibr" rid="article-19552.r43">[43]</xref></p>
      </sec>
      <sec id="article-19552.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Cicatricial pemphigoid is a chronic, progressive disease that results in scarring. Patients require long-term follow-up to monitor for complications as a result of scarring and possible relapse. Due to the potentially serious complications that can arise with cicatricial pemphigoid, it is recommended that therapy is initiated early and aggressively. Patients benefit from a multidisciplinary approach to treatment. Although some patients benefit from immunosuppressive treatment and even have long-term remission, some patients have a refractory disease without a&#x000a0;response&#x000a0;of disease activity&#x000a0;or only temporary control of disease activity with a given treatment.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref></p>
      </sec>
      <sec id="article-19552.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Oral mucosal complications include painful scarring lesions and adhesion formation causing limitation in movement.</p>
        <p>Gingival complications include caries, loss of gingival tissue, and alveolar bone and tooth loss.</p>
        <p>Ocular complications include irritation, decreased tear and mucin production, secondary infection,&#x000a0;symblepharons, ankyloblepharons, corneal irritation, corneal neovascularization, corneal ulcers, and&#x000a0;blindness.</p>
        <p>Nasal complications include discharge, epistaxis, crust formation, chronic sinusitis, scarring, and impaired air flow.</p>
        <p>Pharyngeal complications include hoarseness, loss of voice, supraglottic stenosis, and&#x000a0;airway compromise.</p>
        <p>Esophageal complications include dysphagia, odynophagia, aspiration, and stricture formation.</p>
        <p>Anogenital complications include painful ulcerations, stenosis, and stricture formation.</p>
      </sec>
      <sec id="article-19552.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>A&#x000a0;multidisciplinary approach to treatment strategy is recommended in patients with cicatricial pemphigoid to achieve optimal care. A thorough physical examination and a full review of systems will guide&#x000a0;the determination of&#x000a0;appropriate specialty care. Dermatology, ophthalmology, dentistry, otolaryngology, gastroenterology, colorectal surgery, and gynecology may comprise the treating team. It is important to recognize that control of disease activity through medical therapy should be achieved before embarking on surgical correction of adhesions or strictures. Surgical interventions may further flare the active disease.<xref ref-type="bibr" rid="article-19552.r11">[11]</xref></p>
      </sec>
      <sec id="article-19552.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be counseled on the chronic nature of cicatricial pemphigoid, its possible recalcitrant course, and serious complications. Due to potentially serious complications, the patient should be counseled to remain compliant with medical therapy and maintain regular follow-up visits with the appropriate specialists. Patients should be educated on proper oral and ocular hygiene as clinically appropriate. To achieve enhanced compliance with medical therapies, patients should be educated regarding adverse effects and proper usage of their medications.</p>
      </sec>
      <sec id="article-19552.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cicatricial pemphigoid is a serious disorder that is progressive and can lead to dysfunction of many organs, including blindness. The condition is best managed by an interprofessional team that includes nurses and pharmacists. Most patients require high dose steroids and other biological agents to prevent symptoms. These drugs themselves have a number of adverse effects that also need to be monitored. The quality of life of patients with cicatricial pemphigoid is poor and anecdotal data indicate that premature death from complications is common.</p>
      </sec>
      <sec id="article-19552.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19552&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19552">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/cicatricial-pemphigoid-autoimmune-blistering-disease-of-the-skin-and-mucous-membranes/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19552">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19552/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19552">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19552.s17">
        <fig id="article-19552.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Bullous Pemphigoid <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pemphigoid" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19552.s18">
        <title>References</title>
        <ref id="article-19552.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balding</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Prost</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bedane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aberdam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Giudice</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain.</article-title>
            <source>J Invest Dermatol</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>106</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-6</page-range>
            <pub-id pub-id-type="pmid">8592065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Domloge-Hultsch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gammon</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Briggaman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease.</article-title>
            <source>J Clin Invest</source>
            <year>1992</year>
            <month>Oct</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>1628</fpage>
            <page-range>1628-33</page-range>
            <pub-id pub-id-type="pmid">1401088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyagi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhol</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Natarajan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Livir-Rallatos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1996</year>
            <month>Dec</month>
            <day>10</day>
            <volume>93</volume>
            <issue>25</issue>
            <fpage>14714</fpage>
            <page-range>14714-9</page-range>
            <pub-id pub-id-type="pmid">8962120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaillant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Labeille</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bedane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arbeille</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Denoeux</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lorette</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonnetblanc</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Prost</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group.</article-title>
            <source>Arch Dermatol</source>
            <year>1995</year>
            <month>Jan</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-52</page-range>
            <pub-id pub-id-type="pmid">7826096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wever</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weidenthaler-Barth</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Br&#x000f6;cker</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany.</article-title>
            <source>Arch Dermatol</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>131</volume>
            <issue>8</issue>
            <fpage>957</fpage>
            <page-range>957-8</page-range>
            <pub-id pub-id-type="pmid">7669112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laskaris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sklavounou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stratigos</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bullous pemphigoid, cicatricial pemphigoid, and pemphigus vulgaris. A comparative clinical survey of 278 cases.</article-title>
            <source>Oral Surg Oral Med Oral Pathol</source>
            <year>1982</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>656</fpage>
            <page-range>656-62</page-range>
            <pub-id pub-id-type="pmid">6760033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Shifera</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Okeagu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Incidence and Clinical Characteristics of Ocular Involvement in Mucous Membrane Pemphigoid.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2019</year>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>821</fpage>
            <page-range>821-825</page-range>
            <pub-id pub-id-type="pmid">29672212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XS</given-names>
              </name>
              <name>
                <surname>Hammerberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>High frequency of HLA-DQB1*0301 allele in patients with pure ocular cicatricial pemphigoid.</article-title>
            <source>Dermatology</source>
            <year>1994</year>
            <volume>189 Suppl 1</volume>
            <fpage>99</fpage>
            <page-range>99-101</page-range>
            <pub-id pub-id-type="pmid">8049575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cicatricial pemphigoid sera specifically react with the most C-terminal portion of BP180.</article-title>
            <source>J Dermatol Sci</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-64</page-range>
            <pub-id pub-id-type="pmid">12788530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000e9;dane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Balding</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Prost</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bonnetblanc</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Eady</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Giudice</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida.</article-title>
            <source>J Invest Dermatol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>901</fpage>
            <page-range>901-7</page-range>
            <pub-id pub-id-type="pmid">9182819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleming</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Korman</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Cicatricial pemphigoid.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>571</fpage>
            <page-range>571-91; quiz 591-4</page-range>
            <pub-id pub-id-type="pmid">11004612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhol</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Dans</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Giancotti</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4.</article-title>
            <source>J Immunol</source>
            <year>2000</year>
            <month>Sep</month>
            <day>01</day>
            <volume>165</volume>
            <issue>5</issue>
            <fpage>2824</fpage>
            <page-range>2824-9</page-range>
            <pub-id pub-id-type="pmid">10946315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sogame</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirako</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsuruta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsuchisaka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tsubota</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukumoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sotozono</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Integrin &#x003b2;4 is a major target antigen in pure ocular mucous membrane pemphigoid.</article-title>
            <source>Eur J Dermatol</source>
            <year>2016</year>
            <month>Jun</month>
            <day>01</day>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-53</page-range>
            <pub-id pub-id-type="pmid">27193492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Cicatricial pemphigoid.</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>1986</year>
            <volume>84</volume>
            <fpage>527</fpage>
            <page-range>527-663</page-range>
            <pub-id pub-id-type="pmid">3296406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallagher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shklar</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Oral involvement in mucous membrane pemphigoid.</article-title>
            <source>Clin Dermatol</source>
            <year>1987</year>
            <season>Jan-Mar</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-27</page-range>
            <pub-id pub-id-type="pmid">3552187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mondino</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Linstone</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Ocular pemphigoid.</article-title>
            <source>Clin Dermatol</source>
            <year>1987</year>
            <season>Jan-Mar</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-35</page-range>
            <pub-id pub-id-type="pmid">3552188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Upper aerodigestive tract manifestations of cicatricial pemphigoid.</article-title>
            <source>Ann Otol Rhinol Laryngol</source>
            <year>1988</year>
            <season>Sep-Oct</season>
            <volume>97</volume>
            <issue>5 Pt 1</issue>
            <fpage>493</fpage>
            <page-range>493-9</page-range>
            <pub-id pub-id-type="pmid">3052224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazor</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Varvares</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Mackool</surname>
                <given-names>BT</given-names>
              </name>
            </person-group>
            <article-title>Management of airway obstruction in cicatricial pemphigoid.</article-title>
            <source>Laryngoscope</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>106</volume>
            <issue>8</issue>
            <fpage>1014</fpage>
            <page-range>1014-7</page-range>
            <pub-id pub-id-type="pmid">8699892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hardy</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Pingree</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Benign mucous membrane pemphigoid.</article-title>
            <source>Arch Dermatol</source>
            <year>1971</year>
            <month>Nov</month>
            <volume>104</volume>
            <issue>5</issue>
            <fpage>467</fpage>
            <page-range>467-75</page-range>
            <pub-id pub-id-type="pmid">5120174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lever</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Pemphigus and pemphigoid. A review of the advances made since 1964.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1979</year>
            <month>Jul</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-31</page-range>
            <pub-id pub-id-type="pmid">387823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bean</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Waisman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cicatricial pemphigoid. Immunofluorescent studies.</article-title>
            <source>Arch Dermatol</source>
            <year>1972</year>
            <month>Aug</month>
            <volume>106</volume>
            <issue>2</issue>
            <fpage>195</fpage>
            <page-range>195-9</page-range>
            <pub-id pub-id-type="pmid">4558699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leonard</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gilkes</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Haffenden</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>McMinn</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The relationship between linear IgA disease and benign mucous membrane pemphigoid.</article-title>
            <source>Br J Dermatol</source>
            <year>1984</year>
            <month>Mar</month>
            <volume>110</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <page-range>307-14</page-range>
            <pub-id pub-id-type="pmid">6365149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimanovich</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nitz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>700</fpage>
            <page-range>700-705.e3</page-range>
            <pub-id pub-id-type="pmid">28676329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yasukochi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teye</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Immunological Studies of 332 Japanese Patients Tentatively Diagnosed as Anti-BP180-type Mucous Membrane Pemphigoid: A Novel BP180 C-terminal Domain Enzyme-linked Immunosorbent Assay.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2016</year>
            <month>Aug</month>
            <day>23</day>
            <volume>96</volume>
            <issue>6</issue>
            <fpage>762</fpage>
            <page-range>762-7</page-range>
            <pub-id pub-id-type="pmid">26984589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sezin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Egozi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hillou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Avitan-Hersh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Anti-laminin-332 mucous membrane pemphigoid developing after a diphtheria tetanus vaccination.</article-title>
            <source>JAMA Dermatol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>149</volume>
            <issue>7</issue>
            <fpage>858</fpage>
            <page-range>858-62</page-range>
            <pub-id pub-id-type="pmid">23700098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knudson</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kalaaji</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The management of mucous membrane pemphigoid and pemphigus.</article-title>
            <source>Dermatol Ther</source>
            <year>2010</year>
            <season>May-Jun</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-80</page-range>
            <pub-id pub-id-type="pmid">20597945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aufdemorte</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>De Villez</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Parel</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Modified topical steroid therapy for the treatment of oral mucous membrane pemphigoid.</article-title>
            <source>Oral Surg Oral Med Oral Pathol</source>
            <year>1985</year>
            <month>Mar</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>256</fpage>
            <page-range>256-60</page-range>
            <pub-id pub-id-type="pmid">3885134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Assmann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Megahed</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Topical tacrolimus for oral cicatricial pemphigoid.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>674</fpage>
            <page-range>674-6</page-range>
            <pub-id pub-id-type="pmid">15550151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogers</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Seehafer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>HO</given-names>
              </name>
            </person-group>
            <article-title>Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1982</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-23</page-range>
            <pub-id pub-id-type="pmid">7037880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Megahed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmiedeberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-9</page-range>
            <pub-id pub-id-type="pmid">11464188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nottage</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hammersmith</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Murchison</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Felipe</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Penne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raber</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Treatment of mucous membrane pemphigoid with mycophenolate mofetil.</article-title>
            <source>Cornea</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>810</fpage>
            <page-range>810-5</page-range>
            <pub-id pub-id-type="pmid">23132447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasadhika</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kempen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Liesegang</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Pujari</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Jabs</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Levy-Clarke</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Suhler</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Azathioprine for ocular inflammatory diseases.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>4</issue>
            <fpage>500</fpage>
            <page-range>500-509.e2</page-range>
            <pub-id pub-id-type="pmid">19570522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pujari</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kempen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Gangaputra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suhler</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Jabs</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Levy-Clarke</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Cyclophosphamide for ocular inflammatory diseases.</article-title>
            <source>Ophthalmology</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>117</volume>
            <issue>2</issue>
            <fpage>356</fpage>
            <page-range>356-65</page-range>
            <pub-id pub-id-type="pmid">19969366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Letko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miserocchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Daoud</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Christen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.</article-title>
            <source>Clin Immunol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>111</volume>
            <issue>3</issue>
            <fpage>303</fpage>
            <page-range>303-10</page-range>
            <pub-id pub-id-type="pmid">15183151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maleki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lasave</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stephenson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Anesi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Management of Ocular Cicatricial Pemphigoid with Intravenous Immunoglobulin Monotherapy.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2019</year>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>636</fpage>
            <page-range>636-642</page-range>
            <pub-id pub-id-type="pmid">29517945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rubbert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scharffetter-Kochanek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krieg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hunzelmann</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-5</page-range>
            <pub-id pub-id-type="pmid">11756956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Drouet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sparsa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bonnetblanc</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>B&#x000e9;dane</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2007</year>
            <volume>87</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-5</page-range>
            <pub-id pub-id-type="pmid">17225020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haberman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Swerlick</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kharod-Dholakia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP).</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>May</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>835</fpage>
            <page-range>835-40</page-range>
            <pub-id pub-id-type="pmid">26936298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shetty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>68</volume>
            <issue>3</issue>
            <fpage>499</fpage>
            <page-range>499-506</page-range>
            <pub-id pub-id-type="pmid">23200198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roenigk</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Bergfeld</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita. Report of three cases and review of all published cases.</article-title>
            <source>Arch Dermatol</source>
            <year>1971</year>
            <month>Jan</month>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">4321800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joseph</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Sathyan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goma Kumar</surname>
                <given-names>KU</given-names>
              </name>
            </person-group>
            <article-title>Linear IgA dermatosis adult variant with oral manifestation: A rare case report.</article-title>
            <source>J Oral Maxillofac Pathol</source>
            <year>2015</year>
            <season>Jan-Apr</season>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-7</page-range>
            <pub-id pub-id-type="pmid">26097313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos-Castell&#x000f3;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ortiz-Nieva</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fres&#x000e1;n</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Villalvazo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garfias</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Navas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez-Mart&#x000ed;nez</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Ocular involvement and blindness secondary to linear IgA dermatosis.</article-title>
            <source>J Ophthalmol</source>
            <year>2010</year>
            <volume>2010</volume>
            <fpage>280396</fpage>
            <pub-id pub-id-type="pmid">21234343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19552.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiore</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced pemphigoid. A spectrum of diseases.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>105</volume>
            <issue>12</issue>
            <fpage>1660</fpage>
            <page-range>1660-3</page-range>
            <pub-id pub-id-type="pmid">3318771</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
